Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Fong

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Seminars in Perinatology|July 31, 2004
Potential tissue-engineering applications for neonatal surgeryChristopher Breuer, Tiffany Anthony, Peter Fong
Clinical Lung Cancer|September 15, 2005
Histone deacetylase inhibitors: emerging anticancer therapeutic agents?Rebecca Kristeleit, Peter Fong, G Wynne Aherne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
HDAC inhibitors and cardiac safetyRhoda Molife, Peter Fong, Michelle Scurr, et al.
Clinical Genitourinary Cancer|March 24, 2012
Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene statusReuben J Broom, Imogen Caldwell, Fritha Hanning, et al.
Journal of Cancer|February 25, 2014
The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate CancerRoss Lawrenson, Zuzana Obertová, Charis Brown, et al.
Journal of Pediatric Surgery|May 4, 2005
Development of a parathyroid hormone-controlled release system as a potential surgical treatment for hypoparathyroidismTiffany Anthony, Peter Fong, Amit Goyal, et al.
The Journal of Surgical Research|August 28, 2007
Development of PTH eluting microspheres for the treatment of hypoparathyroidismPeter Fong, Amit Goyal, Matthew Brennan, et al.
Gynecologic Oncology|September 7, 2013
Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expressionRoseanne Rosario, Michelle Wilson, Wei-Tzu Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agentMark J McKeage, Peter Fong, Mark Jeffery, et al.
Oncology|November 18, 2014
Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand menRoss Lawrenson, Chunhuan Lao, Zuzana Obertová, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Seminars in Perinatology|July 31, 2004
Potential tissue-engineering applications for neonatal surgeryChristopher Breuer, Tiffany Anthony, Peter Fong
Clinical Lung Cancer|September 15, 2005
Histone deacetylase inhibitors: emerging anticancer therapeutic agents?Rebecca Kristeleit, Peter Fong, G Wynne Aherne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
HDAC inhibitors and cardiac safetyRhoda Molife, Peter Fong, Michelle Scurr, et al.
Clinical Genitourinary Cancer|March 24, 2012
Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene statusReuben J Broom, Imogen Caldwell, Fritha Hanning, et al.
Journal of Cancer|February 25, 2014
The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate CancerRoss Lawrenson, Zuzana Obertová, Charis Brown, et al.
Journal of Pediatric Surgery|May 4, 2005
Development of a parathyroid hormone-controlled release system as a potential surgical treatment for hypoparathyroidismTiffany Anthony, Peter Fong, Amit Goyal, et al.
The Journal of Surgical Research|August 28, 2007
Development of PTH eluting microspheres for the treatment of hypoparathyroidismPeter Fong, Amit Goyal, Matthew Brennan, et al.
Gynecologic Oncology|September 7, 2013
Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expressionRoseanne Rosario, Michelle Wilson, Wei-Tzu Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agentMark J McKeage, Peter Fong, Mark Jeffery, et al.
Oncology|November 18, 2014
Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand menRoss Lawrenson, Chunhuan Lao, Zuzana Obertová, et al.
Pageof 3